skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 16.11d (Release date: 2016-11-28)
SearchBox Top
SearchBox Bottom
Bortezomib (Code C1851)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Bortezomib

Definition: A dipeptide boronic acid analogue with antineoplastic activity. Bortezomib reversibly inhibits the 26S proteasome, a large protease complex that degrades ubiquinated proteins. By blocking the targeted proteolysis normally performed by the proteasome, bortezomib disrupts various cell signaling pathways, leading to cell cycle arrest, apoptosis, and inhibition of angiogenesis. Specifically, the agent inhibits nuclear factor (NF)-kappaB, a protein that is constitutively activated in some cancers, thereby interfering with NF-kappaB-mediated cell survival, tumor growth, and angiogenesis. In vivo, bortezomib delays tumor growth and enhances the cytotoxic effects of radiation and chemotherapy.

NCI-GLOSS Definition: A drug used to treat multiple myeloma. It is also used to treat mantle cell lymphoma in patients who have already received at least one other type of treatment and is being studied in the treatment of other types of cancer. Bortezomib blocks several molecular pathways in a cell and may cause cancer cells to die. It is a type of proteasome inhibitor and a type of dipeptidyl boronic acid.

Display Name: Bortezomib

Label: Bortezomib

NCI Thesaurus Code: C1851 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1176309  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid
Bortezomib
BORTEZOMIB
bortezomib
LDP 341
MLN341
PS-341
PS341
Velcade
velcade

External Source Codes: 
CAS Registry Number 179324-69-7 (see NLM ChemIDplus info)
FDA UNII Code 69G8BD63PP
ChEBI ID CHEBI:52717 (see ChEBI info)
NSC Code 681239 (see NCI DTP info)
PDQ Closed Trial Search ID 43560
PDQ Open Trial Search ID 43560 (check for NCI PDQ open clinical trial info)
UMLS CUI C1176309

Other Properties:
Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Multiple Myeloma; Advanced Thyroid Cancer
Chemical_Formula C19H25BN4O4
code C1851
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Bortezomib
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: Yes  

URL: https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1851

Mainbox Bottom